Cargando…
Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT
Fibroblast-to-myofibroblast transition (FMT) is the primary inducer of cardiac fibrosis. ONO-1301, a synthetic prostacyclin agonist, reportedly promotes tissue fibrosis repair by enhancing anti-fibrotic cytokine production. We hypothesized that ONO-1301 attenuates pressure-overloaded cardiac fibrosi...
Autores principales: | Masada, Kenta, Miyagawa, Shigeru, Sakai, Yoshiki, Harada, Akima, Kanaya, Tomomitsu, Sawa, Yoshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558785/ https://www.ncbi.nlm.nih.gov/pubmed/33102614 http://dx.doi.org/10.1016/j.omtm.2020.09.005 |
Ejemplares similares
-
Administration of Slow-Release Synthetic Prostacyclin Agonist Promoted Angiogenesis and Skeletal Muscle Regeneration for Limb Ischemia
por: Nakagawa, Takaya, et al.
Publicado: (2020) -
Combined administration of laminin-221 and prostacyclin agonist enhances endogenous cardiac repair in an acute infarct rat heart
por: Sougawa, Nagako, et al.
Publicado: (2021) -
A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart
por: Fukushima, Satsuki, et al.
Publicado: (2015) -
Prostacyclin Analogue–Loaded Nanoparticles Attenuate Myocardial Ischemia/Reperfusion Injury in Rats
por: Yajima, Shin, et al.
Publicado: (2019) -
Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension
por: Kanaya, Tomomitsu, et al.
Publicado: (2021)